Study of Cabozantinib (XL184) in Adults With Advanced Malignancies
Study sponsor: Exelixis
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2013-05Actual
Enrollment · participants730Actual
Source updated2024-04-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.